Literature DB >> 33363002

Microbiome Related Cytotoxically Active CD8+ TIL Are Inversely Associated With Lung Cancer Development.

Leliang Zheng1,2,3, Jiaqi Xu1,3,4,5, Buqing Sai1,3,4,5, Yinghong Zhu1,3,4,5, Lujuan Wang1,3,4,5, Na Yin1,3,4,5, Fenglei Yu2,6, Wen Zhou1,3,4,5, Minghua Wu1,3,4,5, Jingqun Tang2,6, Juanjuan Xiang1,3,4,5.   

Abstract

Lung cancer is the most common cancer type around the world. Although major advances in cancer therapy, lung cancer has been the largest proportion of all cancer-related deaths. The respiratory tract contains many types of bacteria and a distinct lung microbiome in lung cancer patients was described in many studies. The specific roles of these lung microorganisms in lung cancer progression remain unclear. In this study, we evaluated the effect of inhalation of bronchoalveolar fluid (BAL) in the lung cancer cell growth. The microbiome-based immune and carcinogenesis was examined in tumor-bearing mouse model. We found that inhalation of BAL collected from non-small cell lung cancer (NSCLC) patients altered the lung microbiota and inhibited tumor cell growth. The inhibitory effect was due to the infiltration of CD3 and CD8+ T cells and decrease of M2 macrophages in lungs. The microbial communities of NSCLC BAL inhalation group were dominated by Pasteurella, whereas the microbial communities of non-cancer control and PBS inhalation group were dominated by Delftia. Linear discriminant analysis (LDA) indicated that the genera Pasteurella, Pseudomonas, and Chryseobacterium were increased in NSCLC BAL inhalation group, while genera Delftia, Ezakiella, Blautia, Cloacibacterium, and Microvirga et al. were increased in PBS and Non-cancer group. We demonstrated a significant positive correlation between Pasteurella and cytotoxic CD8+ TIL and a negative correlation with M2 macrophages. Coriobacteriaceae was positively correlated with M2 macrophages and negatively correlated with CD8+ cells. The abundance of Pasteurella was negatively correlated with tumor cell growth. Our findings provide a promising strategy that can be used as a therapeutic vaccine for lung cancer patients.
Copyright © 2020 Zheng, Xu, Sai, Zhu, Wang, Yin, Yu, Zhou, Wu, Tang and Xiang.

Entities:  

Keywords:  Pasteurella; TIL; lung cancer; microbiome; therapeutic vaccine

Year:  2020        PMID: 33363002      PMCID: PMC7756114          DOI: 10.3389/fonc.2020.531131

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  32 in total

1.  Commensal Microbiota Promote Lung Cancer Development via γδ T Cells.

Authors:  Chengcheng Jin; Georgia K Lagoudas; Chen Zhao; Susan Bullman; Arjun Bhutkar; Bo Hu; Samuel Ameh; Demi Sandel; Xu Sue Liang; Sarah Mazzilli; Mark T Whary; Matthew Meyerson; Ronald Germain; Paul C Blainey; James G Fox; Tyler Jacks
Journal:  Cell       Date:  2019-01-31       Impact factor: 41.582

Review 2.  The bacterial microbiota in inflammatory lung diseases.

Authors:  Gary B Huffnagle; Robert P Dickson
Journal:  Clin Immunol       Date:  2015-06-26       Impact factor: 3.969

Review 3.  The microbiome and lung cancer.

Authors:  Abhiram Maddi; Amarpreet Sabharwal; Timothy Violante; Sunita Manuballa; Robert Genco; Santosh Patnaik; Sai Yendamuri
Journal:  J Thorac Dis       Date:  2019-01       Impact factor: 2.895

Review 4.  The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy.

Authors:  Vancheswaran Gopalakrishnan; Beth A Helmink; Christine N Spencer; Alexandre Reuben; Jennifer A Wargo
Journal:  Cancer Cell       Date:  2018-04-09       Impact factor: 31.743

Review 5.  Tumour-associated macrophages as treatment targets in oncology.

Authors:  Alberto Mantovani; Federica Marchesi; Alberto Malesci; Luigi Laghi; Paola Allavena
Journal:  Nat Rev Clin Oncol       Date:  2017-01-24       Impact factor: 66.675

6.  Agonist anti-GITR antibody significantly enhances the therapeutic efficacy of Listeria monocytogenes-based immunotherapy.

Authors:  Rajeev Shrimali; Shamim Ahmad; Zuzana Berrong; Grigori Okoev; Adelaida Matevosyan; Ghazaleh Shoja E Razavi; Robert Petit; Seema Gupta; Mikayel Mkrtichyan; Samir N Khleif
Journal:  J Immunother Cancer       Date:  2017-08-15       Impact factor: 13.751

7.  Modulation of the intestinal microbiota alters colitis-associated colorectal cancer susceptibility.

Authors:  Joshua M Uronis; Marcus Mühlbauer; Hans H Herfarth; Tara C Rubinas; Gieira S Jones; Christian Jobin
Journal:  PLoS One       Date:  2009-06-24       Impact factor: 3.240

Review 8.  Why cancer and inflammation?

Authors:  Seth Rakoff-Nahoum
Journal:  Yale J Biol Med       Date:  2006-12

9.  Characterizing human lung tissue microbiota and its relationship to epidemiological and clinical features.

Authors:  Guoqin Yu; Mitchell H Gail; Dario Consonni; Michele Carugno; Michael Humphrys; Angela C Pesatori; Neil E Caporaso; James J Goedert; Jacques Ravel; Maria Teresa Landi
Journal:  Genome Biol       Date:  2016-07-28       Impact factor: 13.583

10.  Interaction between the microbiome and TP53 in human lung cancer.

Authors:  K Leigh Greathouse; James R White; Ashely J Vargas; Valery V Bliskovsky; Jessica A Beck; Natalia von Muhlinen; Eric C Polley; Elise D Bowman; Mohammed A Khan; Ana I Robles; Tomer Cooks; Bríd M Ryan; Noah Padgett; Amiran H Dzutsev; Giorgio Trinchieri; Marbin A Pineda; Sven Bilke; Paul S Meltzer; Alexis N Hokenstad; Tricia M Stickrod; Marina R Walther-Antonio; Joshua P Earl; Joshua C Mell; Jaroslaw E Krol; Sergey V Balashov; Archana S Bhat; Garth D Ehrlich; Alex Valm; Clayton Deming; Sean Conlan; Julia Oh; Julie A Segre; Curtis C Harris
Journal:  Genome Biol       Date:  2018-08-24       Impact factor: 13.583

View more
  1 in total

Review 1.  The Role of Respiratory Microbiota in Lung Cancer.

Authors:  Dan Wang; Jingyi Cheng; Jia Zhang; Fangyu Zhou; Xiao He; Ying Shi; Yongguang Tao
Journal:  Int J Biol Sci       Date:  2021-08-25       Impact factor: 6.580

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.